Humacyte’s (HUMA) Buy Rating Reiterated at HC Wainwright

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $15.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 400.00% from the company’s previous close.

A number of other equities analysts also recently issued reports on the stock. Benchmark reiterated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Performance

NASDAQ:HUMA opened at $3.00 on Wednesday. Humacyte has a 1 year low of $2.81 and a 1 year high of $9.97. The stock has a fifty day moving average price of $4.09 and a two-hundred day moving average price of $4.77. The stock has a market capitalization of $377.58 million, a price-to-earnings ratio of -2.24 and a beta of 1.36.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Humacyte by 85.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,825 shares of the company’s stock valued at $1,024,000 after buying an additional 93,283 shares during the last quarter. Waverly Advisors LLC lifted its position in shares of Humacyte by 331.9% in the fourth quarter. Waverly Advisors LLC now owns 274,579 shares of the company’s stock valued at $1,387,000 after acquiring an additional 211,009 shares in the last quarter. Woodline Partners LP lifted its position in shares of Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock valued at $14,386,000 after acquiring an additional 2,000,268 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Humacyte during the fourth quarter valued at $132,000. Finally, ProShare Advisors LLC increased its position in Humacyte by 30.4% during the 4th quarter. ProShare Advisors LLC now owns 30,852 shares of the company’s stock worth $156,000 after purchasing an additional 7,188 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.